Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Roboclinic vs Shapely

Roboclinic
Graded #234

Lower grade

vs+0.4000000000000057
Shapely
Graded #225

Higher grade

The verdict

Shapely takes it — 65.4/100 to 65/100, but only just.

Shapely grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Shapely is a GLP-1 telehealth platform founded by Dr. Roboclinic is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueRoboclinic +5
50
45
Dose & formulationRoboclinic +22
75
53
Clinical oversightShapely +10
84
94
Labs & monitoringShapely +20
53
73
FulfillmentShapely +3
75
78
Contract termsShapely +8
47
55
Roboclinic · left barShapely · right bar

The numbers

MetricRoboclinicShapely
WeighScore65/10065.4/100
GradeCC
Scorecard rank#234#225
Semaglutide$179/mo (12-month plan, compounded)Not disclosed
Tirzepatide$299/mo (12-month plan, compounded)Not disclosed
CoverageCoverage not published4 states
Brand-name accessCompounded onlyYes
Oral / sublingualYesInjection only
Roboclinic

Graded #234 · C

Strengths

  • Compounded semaglutide from $179/mo and tirzepatide from $299/mo on 12-month plans
  • One all-in price bundles the provider consult, prescription, and delivery
  • Offers both injectable and oral (tablet) compounded semaglutide
  • 'Same price, every dose' means your cost does not rise as the dose increases
  • AI-first intake with board-certified provider review; no insurance necessary

Where it loses points

  • Lowest rates require a 12-month plan; month-to-month runs $299/mo (semaglutide) to $399/mo (tirzepatide)
  • Individual compounding pharmacies are not named; fulfillment is routed through OpenLoop Health
  • No published per-state list; site claims 'all 50 states, restrictions apply' and gates doctor review by region
  • Refunds limited to your most recent billing cycle; none for used or partially used periods
  • Operated by BrickFi, Inc., a newer brand with limited independent track record
Shapely

Graded #225 · C

Strengths

  • Founded by Dr. Justin Zaghi, MD/MBA — Harvard-trained, board-certified in internal medicine and obesity medicine, with Medical Director Ana Lisa
  • Brand-name GLP-1s (Wegovy, Ozempic, Zepbound, Mounjaro, Foundayo) covered by major PPO and Medicare at copay
  • Compounded semaglutide from $99/month with free 2-day shipping, syringes, and supplies included via 503A/503B pharmacy
  • 1:1 registered dietitian (RDN) and monthly video provider visits included in every plan; unlimited chat and app support
  • Cellular smart scale provided to qualifying patients for ongoing weight tracking throughout the program

Where it loses points

  • Currently available only in California, Florida, New York, and Texas — 46 states unserved despite announced expansion
  • Telehealth subscription ($99/mo self-pay, $49 first-month promo) is charged separately from compounded medication cost
  • Labs not included — $75 flat rate for uninsured patients; baseline bloodwork may be required before prescribing
  • No LegitScript certification found on any public page
  • Compounding pharmacy partner not named publicly; 503A/503B status claimed but specific pharmacy undisclosed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard